Ocugen, Inc. Common Stock
Here’s whether Ocugen, Inc. Common Stock (OCGN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.92% over 10 days); RSI 61 — healthy momentum range; strong 1-year return of +37.6%. Concerns: trading below the 200-day MA (long-term downtrend); declining volume on rally — weak conviction (0.79x 30d avg). Currently 49.0% off its 52-week high. Score: +1/7.
OCGN is trading below its 200-day MA ($1.51) — a key warning sign the longer-term trend is under pressure. An RSI of 61.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +37.6% compares to +20.5% for SPY (beat the market by 17.1%). The current 49.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.